【摘要】 目的:探讨肿瘤院内感染患者的2006年度细菌药敏试验结果指导2007年度经验性抗感染治疗的价值。方法:根据2006年这类患者的细菌药敏试验结果,2007年本研究选择哌拉西林/他唑巴坦为肿瘤院内感染患者的首选经验性治疗方案,同时与"经典"的头孢他定+阿米卡星方案做随机对比。结果:2007年以哌拉西林/他唑巴坦治疗者80例,有效率为86.2%,对照组头孢他定+阿米卡星治疗者因前30例有效率仅46.7%而提前中止,两组有效率比较P<0.005。与此相对应,2006年哌拉西林/他唑巴坦、头孢他定对细菌的敏感性覆盖率分别为85.2%、54.5%。结论:2006年度肿瘤院内感染患者细菌药敏试验敏感性覆盖率高的药物,作为2007年度肿瘤院内感染患者经验性抗感染治疗首选药物时,有效率也高。更多还原

【Abstract】 Objective To investigate the value of applying the bacterial sensitivity test results in patients with tumor complicated with nosocomial infection in 2006 to guide the empirical anti-infective therapy in 2007. Methods According to the results of antimicrobial susceptibility test in 2006,patients with tumor complicated with nosocomial infection in 2007 were randomly assigned to received piperacillin/tazobactam (test group,n=80) or ceftazidime + amikacin (control group). Results In 2007,the effective rate of piperacillin/tazobactam was 86.2% in 80 cases,which was higher than that of ceftazidime + amikacin (only 46.7% ) in the first 30 cases (stopped ahead of schedule)(P<0.005). Correspondingly,the sensitivities of piperacillin/tazobactam and ceftazidime were 85.2% and 54.5% in 2006. Conclusion The effective rate of empirical anti-infective drugs,which were based on the bacterial sensitivity test results conducted in patients with tumor complicated with nosocomial infection in 2006,was higher in 2007.更多还原